Laura

External validation of nomograms for predicting lymph node invasion (LNI) in prostate cancer patients with negative PSMA PET-CT. What did we find? The Briganti 2023 nomogram is the most accurate! 📊✅ 🔍 Why does it matter? Extended pelvic lymph node dissection (ePLND) is the gold standard for staging but comes with risks. With PSMA PET-CT revolutionizing imaging, we need better predictive tools to avoid unnecessary procedures. 📌 Key Findings: •Among 282 patients, 13% had LNI despite negative PSMA PET-CT. •The Briganti 2023 nomogram outperformed others (C-index: 77% vs. MSKCC 64%, Briganti 2017 69%, Amsterdam-Brisbane-Sydney 64%). •Using a 5% risk cutoff would spare 47% of ePLND procedures while missing only 3.8% of LNI cases! 🚫🔬 ⚖️ Clinical Impact: •Improves decision-making: More precise risk stratification means fewer unnecessary surgeries. •Saves patients from complications: ePLND has side effects; avoiding it when possible is crucial. •Guides personalized treatment: Selecting the right patients for ePLND enhances care quality. 👨‍⚕️ Takeaway: The Briganti 2023 nomogram should be the go-to tool for predicting LNI in prostate cancer patients with negative PSMA PET-CT! 📈 🔗 Read the full study here: sciencedirect.com/science/ar… #ProstateCancer #Urology #PSMAPET #LymphNodeDissection #Nomogram